For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

Deslorelin vs MGF

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

DeslorelinMGF
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asSuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRHMechano Growth Factor, IGF-1Ec, Insulin-like Growth Factor splice variant
EvidenceResearch-stagePreclinical only
Dosing range50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset100mcg–300mcg mcg, Post-workout (within 30–60 minutes of training), 3–4x weekly
AdministrationSubcutaneous implant (veterinary), Subcutaneous injectionIntramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution)
Key side effectsHot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritabilityLocalized muscle swelling at injection site (normal response), Hypoglycemia (less pronounced than IGF-1 DES but present), Very short half-life means side effects are brief, Potential overuse injury if post-workout injection is used consistently without adequate recovery
Cited sources2 references3 references

Key differences

  • Evidence level differs: Deslorelin is research-stage, while MGF is preclinical only.
  • Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; MGF — Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution).
  • Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; MGF is Post-workout (within 30–60 minutes of training), 3–4x weekly.
  • Research depth: this profile cites 2 sources for Deslorelin vs 3 for MGF.

How each works

Deslorelin

Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.

MGF

MGF is encoded by the IGF-1 gene but produced via alternative splicing that generates a unique 49-amino acid C-terminal E-peptide (Ec peptide). The Ec peptide has distinct biological activity from the IGF-1 domain — it directly activates satellite cell proliferation through a receptor pathway separate from the standard IGF-1R. Studies in rodents show that local MGF injection produces significant muscle hypertrophy in the injected limb without systemic IGF-1 elevation. MGF expression spikes within 30 minutes of resistance exercise and declines over 24–48 hours — aligning precisely with the post-exercise anabolic window.

Read the full Deslorelin profileRead the full MGF profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.